Aims: The aim of this meta-analysis was to compare the midterm clinical outcomes of patients treated with an everolimus-eluting bioresorbable vascular scaffold (BVS) versus an everolimus-eluting metallic stent (EES) for percutaneous coronary interventions.
Introduction
The everolimus-eluting bioresorbable vascular scaffold (BVS) (Absorb™; Abbott Vascular, Santa Clara, CA, USA) is the only fully bioresorbable platform to have received approval for clinical use from regulatory agencies in both Europe and the USA 1 . Indeed, the BVS device has been evaluated in a number of randomised trials in patients with obstructive coronary artery disease with comparison against the widely used everolimus-eluting metallic stent (EES), showing broadly comparable clinical outcomes at 12 months after implantation 2, 3 .
By providing only transient support of the dilated vessel, it has been hypothesised that bioresorbable scaffolds might improve long-term vessel healing and remodelling, restore vasomotor function of the treated segment, and potentially eliminate the accrual of late adverse events after percutaneous coronary intervention (PCI) in comparison with conventional drug-eluting stent (DES) platforms 4 . Recently, however, a dedicated randomised trial failed to demonstrate either physiological or clinical advantages at three years with BVS as compared to EES 5 .
In the light of a number of trial reports investigating comparative efficacy beyond one year that have recently become available, we performed a meta-analysis of randomised trials to evaluate the efficacy and safety of BVS as compared to conventional metallic stents.
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Methods SEARCH STRATEGY AND SELECTION CRITERIA We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), scientific sessions abstracts and relevant websites (www.cardiosource.com, www.clinicaltrialresults.org, www.escardio.org, www.tctmd.com, www.theheart.org) for randomised trials comparing everolimus-eluting bioresorbable scaffolds versus conventional EES for PCI without restrictions concerning language or publication status. Inclusion criteria were: (1) randomised design, and (2) follow-up >12 months. Comparisons other than BVS versus EES were ineligible. We updated a previous search of scientific databases for articles dealing with the topic under investigation published or posted between November 2006 and October 2015 3 up to May 2017. The reference lists from all eligible studies were checked to identify further citations.
DATA COLLECTION AND ASSESSMENT OF RISK OF BIAS
Two investigators (S. Cassese and R.A. Byrne) independently assessed publications for eligibility at title and/or abstract level. Divergences were resolved by consensus. Studies that met inclusion criteria were selected for further analysis. The same two investigators independently evaluated the risk of bias for each study in accordance with The Cochrane Collaboration method 6 . Composite quality scores were not assigned 7 .
OUTCOMES
For the current report, the primary efficacy outcome was target lesion failure (TLF), the device-oriented composite endpoint including cardiac death, target vessel myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (ID-TLR); the primary safety outcome was definite/probable stent (scaffold) thrombosis (ST). Secondary outcomes were the individual components of the primary efficacy outcome. Other outcomes of interest were death, MI, TLR and any revascularisation. All endpoints were evaluated according to the intention-to-treat principle and the definitions reported in the original protocols.
STATISTICAL ANALYSIS
Odds ratios (ORs) with 95% confidence intervals (95% CI) were used to compare outcomes of interest between BVS and EES and pooled using the Mantel-Haenszel fixed-effect model and the Hartung-Knapp random-effect model with or without the modification of the variance estimate, as appropriate 8, 9 . For the primary efficacy and safety outcomes, we also derived the numbers needed to treat (or to harm) 10 from random-effects pooled risk ratios and the risk observed in the control group of the Amsterdam Investigator-initiateD Absorb strategy (AIDA) all-comers trial 11 , which had a less selective patient inclusion than the other trials. All outcomes were primarily evaluated at the longest follow-up available. In addition, the ORs for primary outcomes and ID-TLR were calculated at 12-month and 24-month follow-up, and with landmark analyses beyond 12-month and 24-month follow-up. Heterogeneity between trials was quantified using the I 2 statistic accompanied by a χ 2 test: I 2 values around 25%, 50% and 75% were suggested to indicate low, moderate or high heterogeneity, respectively 12 . In addition, we estimated the between-study variance (τ 2 ). The possibility of small study effects resulting from publication bias or other biases was examined for primary outcomes by means of visual inspection of funnel plots of the ORs of individual trials against their standard errors, accompanied by a statistical test of asymmetry 13 . An influence analysis, in which meta-analysis estimates are computed omitting one study at a time, was performed for primary outcomes. Using a χ 2 test for subgroup by treatment interaction, we determined whether the type of sponsorship (industry-versus investigator-initiated) was associated with estimated ORs of primary outcomes. Finally, we determined the power of our random-effects meta-analysis to detect a pre-specified 25% relative risk reduction of TLF and a 50% relative risk reduction of definite/probable ST conditional on the observed precision of the pooled estimate 14 . This study was reported in compliance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (Supplementary Table 1 ) 15 . All analyses were performed in R, 
Results
The electronic search identified seven randomised trials investigating BVS versus EES with follow-up data beyond one year: two trials reported as full-length manuscripts 5, 11 and five reported as meeting presentations [16] [17] [18] [19] [20] . These trials totalling 5,583 enrolled participants were included ( Supplementary Figure 1) .
The main characteristics of the included trials are described in detail in Supplementary Table 2 . Briefly, PCI patients were randomised to a treatment with BVS (n=3,261) or EES (n=2,322). Individuals randomised to BVS were treated with the Absorb stent 21 , while those randomised to EES were treated with cobaltchromium EES (XIENCE V ® , XIENCE Prime ® or XIENCE Xpedition ® ; Abbott Vascular) (n=2,242) or platinum-chromium EES (PROMUS Element™; Boston Scientific, Marlborough, MA, USA) (n=80) 16 . Three out of seven trials included patients with acute MI 11, 16, 17 . In three trials 5, 16, 18 the primary endpoint consisted of angiographic measures of efficacy, in one trial 17 of imaging measures of efficacy, while the remaining trials were powered for composite clinical outcomes 11, 19, 20 . Two studies scheduled control angiography 36 months after index intervention 5, 20 . One trial 11 had descriptive outcomes data made available after a median followup duration of 24 months, which was included in our analyses.
The definitions used for outcomes are described in detail in Supplementary Table 3 . All interventions were performed in accordance with standard of care, including stent deployment optimisation or use of intravascular imaging techniques, at the operators' discretion or according to protocols. Overall, predilation was performed in 3,556 (97.6%) of 3,640 lesions treated with BVS and in 2,496 (93.2%) of 2,676 lesions treated with EES; postdilation was performed in 2,471 (67.7%) of 3,646 lesions treated with BVS and 1,459 (54.3%) of 2,683 lesions treated with EES. Across included trials, the reported percentages of device success in the BVS group ranged between 92% and 99%, while the percentages of procedural success ranged between 90% and 97%. Anticoagulation during PCI was accomplished through administration of either unfractionated heparin or bivalirudin in all cases. After coronary interventions, aspirin was recommended indefinitely, whilst thienopyridines were prescribed for a period ranging from ≥6 to 12 months. In six trials 5, 11, 16, [18] [19] [20] , a proportion of patients ranging between 17.5% and 41.7% in the BVS group and between 14.0% and 38.1% in the EES group were actually on dual antiplatelet therapy (DAPT) at the time of last available followup. At 12 months, 2,840 (92.3%) of 3,076 patients treated with BVS and 1,977 (91.4%) of 2,161 patients treated with EES were actually on DAPT. At 24 months, 1,343 (49.1%) of 2,732 patients treated with BVS and 791 (44.0%) of 1,795 patients treated with EES were actually on DAPT. All study subjects received standard medical therapies as required. The evaluation of risk of bias among studies is reported in Supplementary Table 4 .
The main characteristics of patients and lesions treated in the original trials are listed in Table 1 . Individuals enrolled were more often male, with a median age of 63.5 years (interquartile range, 58.6-65.0), and about a quarter were diabetics. Approximately one third of cases presented with ACS at the time of index PCI. At baseline angiography, treated lesions displayed a mean diameter stenosis of 70.7%, a reference vessel diameter of 2.70 mm and a length of 14.3 mm. Two thirds of lesions treated had a complex morphology.
OUTCOMES
Among those randomised, 5,452 patients (97.6%) were available for assessment of outcomes of interest. The weighted median follow-up was 26.6 months, ranging between 24 and 36 months.
PRIMARY OUTCOMES
Forest plots for primary outcomes are displayed in Figure 1 . The primary efficacy outcome of TLF occurred in 496 patients (9.1%). Patients treated with BVS versus EES showed a higher risk for TLF (10.1% versus 7.6%; OR 1.35 [1.11-1.65], p=0.0028; I 2 =0%). The risk for TLF with BVS versus EES tended to increase at 12 months (6.4% versus 5.2%; OR 1.23 [0.97-1.56], p=0.08, Supplementary Figure 2A ) and was significantly higher at 24 months (9.5% versus 7.4%; OR 1.32 [1.08-1.61], p=0.007, I 2 = 0%) (Figure 2, Supplementary Figure 2B ). In the period beyond 12 months after implantation, TLF occurred in 115 patients treated with BVS and in 53 patients treated with EES (3.6% versus 2.3%; OR 1.62 [0.96-2.73]; p=0.06, I 2 =19.9%) (Supplementary Figure 2C) . In the period beyond 24 months after implantation, TLF occurred in 18 patients treated with BVS and six patients treated with EES (0.8% versus 0.5%; OR 1.47 [0.51-4.20]; p=0.33, I 2 =0%, data available for 3,316 patients). The number needed to harm to cause one case of TLF with the use of BVS up to an average follow-up of 26.6 months was 38 patients . The random-effects meta-analysis had an 81% power to detect a 25% relative risk reduction of TLF associated with BVS.
The primary safety outcome of definite/probable ST occurred in 94 patients (1.7%). Patients treated with BVS versus EES showed a higher risk for definite/probable ST (2.4% versus 0.7%; OR 3.24 [1.92-5.49], p<0.0001; I 2 =0%). The risk for definite/probable ST with BVS versus EES was increased both at 12-month (1.6% versus 0.6%; OR 2. Figure 3C ). In the period beyond 24 months after implantation, definite/probable ST occurred in two patients treated with BVS and in no patient treated with EES (OR 1.49 [0.15-14.39]; p=0.73, I 2 =0%, data available for 3,296 patients).
The number needed to harm to cause one case of definite/ probable ST with the use of BVS up to an average follow-up Figure 4B ).
SECONDARY OUTCOMES
Forest plots for secondary outcomes are displayed in Figure 3A-Figure 3C . Cardiac death occurred in 73 patients (1.3%).
The risk for cardiac death was not statistically different between patients treated with BVS and those treated with EES (1.2% versus 1.5%; OR 0.89 [0.55-1.43], p=0.56; I 2 =0%).
Target vessel MI occurred in 264 patients (4.8%) and those treated with BVS versus EES showed a higher risk for MI related to the target vessel (5.9% versus 3.3%; OR 1.68 [1.21-2.33], p=0.008; I 2 =0%). Notably, the higher risk for target vessel MI of individuals treated with BVS versus EES persisted even after the exclusion of those events which occurred in the periprocedural phase ( 
OTHER OUTCOMES OF INTEREST
Forest plots for other outcomes of interest are displayed in Supplementary Figure 5A-Supplementary Figure 5D . Patients treated with BVS versus EES showed a higher risk of MI ( 
SMALL STUDY EFFECTS, INFLUENCE, SENSITIVITY AND SUBGROUP ANALYSES
Funnel plots for TLF and definite/probable ST are presented in Supplementary Figure 6A and Supplementary Figure 7A . We found no evidence for small study effects, either by visual inspection of funnel plots or by asymmetry test. The influence analysis demonstrated that no single study significantly altered the direction of the summary ORs for TLF and definite/probable ST, respectively ( Supplementary Figure 6B, Supplementary Figure 7B) . The type of sponsorship for each included trial did not influence the risk estimates for primary outcomes.
Discussion
This meta-analysis of aggregate data investigates the clinical outcomes beyond one year of PCI patients randomised to a percutaneous revascularisation with either BVS or EES. At a median study-level follow-up of 26.6 months, BVS in comparison to EES showed: (i) lower efficacy due to a higher risk of TLF, and (ii) inferior safety due to a higher risk of ST, particularly in the period beyond 12 months after implantation.
BVS provide transient scaffolding of the target lesion during the initial months and years after implantation and then degrade into predominantly inert breakdown products after about three years 2 . Previously, a number of meta-analyses including data from trials enrolling patients with moderate lesion complexity and with follow-up up to one year found BVS associated with an overall clinical efficacy comparable to that of EES although a higher risk of ST was observed, particularly in the first 30 days after implantation 3, 22 . These findings are in broad agreement with those from registries including patients with somewhat more complex disease patterns 23 . In response to these observations, it has been suggested that improved patient selection in conjunction with introduction of dedicated interventional protocols specific to BVS might result in improved performance of current-generation devices 24 . More recently, however, the first randomised trial comparing BVS and EES in relatively straightforward lesion morphologies has reported a higher risk of failure associated with the bioresorbable scaffolds up to three-year follow-up 5 . Notably, at this time point the antirestenotic drug should be completely eluted and the resorption process of BVS nearly completed 21 .
In a study-level meta-analysis including three randomised trials and 21 observational studies 25 , Toyota and colleagues found a higher risk for definite/probable ST and a similar risk for TLF, 16.2 months after the percutaneous implantation of BVS as compared to EES. Similarly, in a recent meta-analysis of aggregate data from seven randomised trials, a PCI with BVS versus EES increased the risk for TLF and definite/probable ST at 24 months 26 .
To shed more light on the performance beyond one year of BVS as compared to EES, we analysed the totality of study-level data from seven randomised trials investigating this issue. The novelty of the present study is twofold: first, we studied efficacy and safety of BVS versus EES at the longest follow-up interval, since three out of seven trials included 5,18,20 had three-year data available for this analysis. Second, the comparable follow-up periods accumulated among included trials allowed further insight into the time-dependent performance of BVS versus EES: indeed, the risk estimations for several outcomes were calculated not only at the longest follow-up but also at specific time points (12 and 24 months) and with two landmark analyses (beyond 12 and 24 months). These are the main differences from previous studies, which analysed efficacy and safety of BVS versus EES within wide ranges of follow-up intervals 26 .
In the present study, at a median follow-up of 26.6 months after index intervention, we found that the use of BVS as compared with EES increased the risk of TLF with a number needed to harm of 38. Interestingly, the higher risk for TLF with BVS was mainly driven by more frequent ID-TLR and target vessel MI and 
. Forest plots of individual components of primary efficacy outcome with BVS versus EES. Odds ratios for cardiac death (A), target vessel myocardial infarction (B), and ischaemia-driven target lesion revascularisation (C) with BVS versus EES. The diamonds indicate the point estimates and the left and the right ends of the lines the 95% confidence intervals. BVS: bioresorbable scaffold; EES: everolimus-eluting stent
only two out of seven trials among those included in this study required per protocol a late angiography 5, 20 . In this regard, the increased incidence of ST is an important driver of these adverse events. Compared to EES, the risk for TLF after BVS implantation increased slightly at 12 months and was significantly higher at 24 months. However, it should be noticed that these results were mostly observed in well-selected patients and lesions, since only one 11 out of seven trials enrolled a relatively broad spectrum of PCI patients more similar to those encountered in routine practice. In this respect, the findings and the magnitude of the treatment effects observed in the present analysis should be interpreted with caution and are not generalisable to higher-risk subsets of patients. Of concern, in PCI patients treated with BVS as compared to EES we observed an increase in the risk of ST, with a number needed to harm of 63. The increased thrombotic risk after BVS implantation was already present at 12-month follow-up and became particularly high in the period beyond one year. Although the mortality rate was low, which prevents this meta-analysis from having sufficient assessment power for this event, an explanation of the lack of impact on mortality of increased risk of ST with BVS is difficult. However, the low number of events and the absence of a long-term follow-up certainly play an important role in this regard. These results merit careful discussion.
First, the occurrence of thrombotic events even >12 months after BVS implantation is in keeping with small observational series describing late adverse events at advanced stages of BVS resorption 27, 28 . Although it is intuitive to expect that adoption of BVS implantation protocols targeted at improving acute mechanical results may impact on short-term outcomes, whether such protocols can modify rates of late thrombotic events remains to be seen. In this regard, a recent post hoc analysis from the AIDA all-comers trial showed that even adhering to good implantation techniques failed to limit the higher thrombotic risk associated with BVS 29 . Second, it remains to be determined if the observed higher risk of ST with BVS is directly attributable to loss of integrity of the stent and/or prolapse within the vessel lumen. In some patients with very late ST 30 , intracoronary imaging of BVS-treated segments demonstrated scaffold discontinuities, malapposition and uncovered struts. Scaffold discontinuities are a relatively common finding during BVS degradation and the relationship to subsequent adverse events is somewhat unclear 31 . In this respect, ongoing studies of intravascular imaging (NCT02683356, NCT02466282, NCT02814578, NCT02894697, and NCT02831218) are likely to be of great value in understanding the late performance of BVS. Third, it is unknown whether this risk of late device thrombosis might be ameliorated by prescription of more potent or prolonged duration of DAPT, especially for certain high-risk subgroups of patients 32 . This issue should be explored further with dedicated studies. For instance, one trial 5 observed absence of late thrombotic events after BVS implantation in patients who never interrupted DAPT up to three years. In this meta-analysis, the risk of ST with BVS was significantly increased both at 12-month and at 24-month follow-up, irrespective of the proportions of patients on DAPT. Finally, the majority of BVS-treated patients suffering from very late ST presented with ST-elevation MI at the time of re-admission. In this respect, the higher risk of MI related to the target vessel treated with BVS as compared to EES found in this report seems attributable to some extent to these late thrombotic events, rather than to periprocedural MI.
Study limitations
The current study has a number of limitations. First, as clinical outcomes in important subgroups were not consistently reported in included trials, an individual patient data meta-analysis is required to determine whether findings vary across different subgroups of patients. Second, the majority of included trials were available as meeting presentations and not as full-length manuscripts. Third, the actual duration of DAPT was not systematically monitored in all trials, precluding firm conclusions regarding a potential benefit of prolonged DAPT or more potent antiplatelet agents for BVStreated patients. Fourth, this study focused only on a single type of bioresorbable scaffold and current findings do not apply to other bioresorbable platforms. Finally, the assessment of publication bias was based on a limited number of trials: this resulted in low power and diminished performance of the asymmetry test.
Conclusions
The results of our meta-analysis suggest that percutaneous coronary intervention with BVS as compared to EES is associated with a higher risk of target lesion failure and myocardial infarction at a median follow-up longer than two years. The risk of definite/ probable ST is also higher with BVS as compared to EES, particularly in the period beyond one year after implantation. Future studies should investigate the influence of specific implantation protocols and more potent and/or prolonged dual antiplatelet therapy on overall clinical outcomes.
Impact on daily practice
The results of our meta-analysis suggest that a percutaneous coronary intervention with bioresorbable vascular scaffolds as compared to everolimus-eluting metallic stents is associated with a higher risk of serious adverse events at a median followup longer than two years. Whether the iterative development of fully bioresorbable scaffolds with improved mechanical and biological properties, the cautious selection of patients and lesions suitable for this technology, the adoption of specific implantation protocols and more potent and/or prolonged dual antiplatelet therapy would impact on clinical outcomes should be the object of future investigations.
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